Influenza News

The incidence of laboratory-confirmed influenza-associated hospital admissions among infants may be more than 2 times higher than current estimates, according to findings from four low- and middle-income countries published in The Lancet Child & Adolescent Health.

A recent report published in Emerging Infectious Diseases detailed a case of likely human-to-human transmission of an influenza A virus with reduced susceptibility to Xofluza between two siblings in Japan.

Xofluza significantly reduced the risk for influenza infection among children aged younger than 12 years and adults living with infected individuals by 86%, according to phase 3 trial findings released by Genentech.

Medical professionals caring for migrant children and their families in holding at the southern border will not vaccinate them against influenza in preparation for the upcoming influenza season, a spokesperson for U.S. Customs and Border Protection, or CBP, confirmed to Infectious Diseases in Children.

In a review published in Science Translational Medicine, researchers summarized key findings and unanswered questions from the 1918 influenza pandemic and discussed how reconstructing the pandemic strain has revealed insights into the potential origin of the virus and the features that made it uniquely fatal.

Sanofi Pasteur, the largest provider of influenza vaccines in the United States, said shipments of its vaccines for the 2019-2020 season will be delayed by around 1 month because of a lag in production.

There are no links between exposure to the 2009 pandemic H1N1 influenza vaccine during pregnancy and early childhood health problems, according to a recent study published in The BMJ.

Sanofi announced that it signed a deal with Roche for exclusive over-the-counter rights to Tamiflu to prevent and treat influenza in the U.S.

Children of parents who received a simple educational handout with information about influenza were more likely to get vaccinated by the end of the influenza season, according to the results of a randomized clinical trial published in Pediatrics.

One dose of Xofluza was well-tolerated and demonstrated comparable efficacy to oseltamivir in children aged 1 to younger than 12 years with influenza, according to findings from a phase 3, multicenter, randomized, double-blind study.